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Abstract
Background: Familial papillary thyroid cancer (fPTC) is recognized as a distinct entity only recently and no fPTC
predisposing genes have been identified. Several potential regions and susceptibility loci for sporadic PTC have
been reported. We aimed to evaluate the role of the reported susceptibility loci and potential risk genomic region
in a Chinese familial multinodular goiter (fMNG) with PTC family.
Methods: We sequenced the related risk genomic regions and analyzed the known PTC susceptibility loci in the
Chinese family members who consented to join the study. These loci included (1) the point mutations of the BRAF
and RET; (2) the possible susceptibility loci to sporadic PTC; and (3) the suggested potential fMNG syndrome with
PTC risk region.
Results: The members showed no mutations in the common susceptible BRAF and RET genomic region, although
contained several different heterozygous alleles in the RET introns. All the members were homozygous for PTC risk
alleles of rs966423 (C) at chromosome 2q35, rs2910164 (C) at chromosome 5q24 and rs2439302 (G) at chromosome
8p12; while carried no risk allele of rs4733616 (T) at chromosome 8q24, rs965513 (A) or rs1867277 (A) at
chromosome 9q22 which were associated with radiation-related PTC. The frequency of the risk allele of rs944289 (T)
but not that of rs116909374 (T) at chromosome 14q13 was increased in the MNG or PTC family members.
Conclusions: Our work provided additional evidence to the genetic predisposition to a Chinese familial form of
MNG with PTC. The family members carried quite a few risk alleles found in sporadic PTC; particularly, homozygous
rs944289 (T) at chromosome 14q13 which was previously shown to be linked to a form of fMNG with PTC.
Moreover, the genetic determinants of radiation-related PTC were not presented in this family.
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PTC is the most prevalent malignancy of the thyroid gland.
There has been an increasing incidence of PTC worldwide
for the past few decades. The etiology of PTC is related
to environmental, hormonal and genetic factors. About
5-15% of PTC patients show a familial occurrence, and
fPTC is recognized as a distinct entity only in recent years
[1,2]. Families with accumulation of PTCs show an
inherited trait of the disease and patients with fPTC often
have early age at disease onset and increased severity in
successive generations, also, fPTC patients frequently
present more aggressive tumors with increased incidence
of multifocality, local invasion, lymph node metastases than
the sporadic PTC [2,3]. Generally, fPTC is diagnosed when
three or more family members have PTC and in the ab-
sence of other known associated syndromes [1,2]. PTC has
a significant gender bias with much more women affected
than men; it is especially suggestive for the familial predis-
position when men or children were diagnosed with PTC
[1,4]. While, because families share the same environment
and a common genetic background, it is difficult to distin-
guish between environmental and genetic contributing fac-
tors, and also because the majority of fPTC pedigrees are
small in size and may present with a variety of additional
benign thyroid nodules, the genetic predisposition to fPTC
is unknown and the molecular alterations at the origin of
the pathology are only now beginning to emerge [1,5,6].
Sporadic PTC is known to be associated with point
mutation of the BRAF genes and chromosomal rear-
rangements of RET/PTC.T h eBRAF encodes a serine/
threonine-protein kinase which plays a role in regulat-
ing the MAP kinase/ERKs signaling pathway and affects
cell division, differentiation and secretion; point muta-
tions in BRAF are found in up to 45% PTC cases [7].
The RET protooncogene is one of the receptor tyrosine
kinases, cell-surface molecules that transduce signals
for cell growth and differentiation; rearrangements of
the RETare found in about 35% of sporadic PTC [7]. Al-
though somatic mutations of the genes like BRAF and
RET exclusively play a causative role in sporadic thyroid
cancer development, germline mutations of single nu-
cleotide polymorphisms (SNPs) in these genes were also
reported to act as modifiers in the cancer process [8,9],
it needs to mention here that in a Chinese population,
SNPs of BRAF were shown to be associated with PTC
[10], and thus it is intriguing to verify these mutations
in fPTC families.
Recent studies based on population stratification have
made progresses to identify several single nucleotide poly-
morphisms (SNPs) associated with PTC risk. For exam-
ples, (1) It was discovered that rs966423 at 2q35, locating
into the intron region of the disrupted in renal carcinoma
3g e n e( DIRC3), was significantly associate with European
nonmedullary thyroid cancer (NMTC) by the genome-
wide studies [11]. DIRC3 predicted a non coding RNA
transcript with unknown function, the first 2 exons of
DIRC3 replaced exon 1 of HSPBAP1 and formed a
DIRC3-HSPBAP1 fusion transcript, which are associated
with chromatin remodeling and stress response; (2) It was
reported that the heterozygosity G/C of SNP rs2910164
at 5q24 within the precursor of microRNA-146a pre-
disposed to PTC by altering expression of miR146a
target genes in the Toll-like receptor and cytokine sig-
naling pathway [12,13]; (3) The genome-wide study also
identified that chromosomal 8q24 was associated with
the risk of various cancers, particularly, rs4733616 at
8q24 was founded to be possibly associated with PTC
risk in 26 European families [14-16]; (4) The rs2439302,
located in the intron of HRG-beta1c at 8p12,was
reported to be associated with neuregulin 1 (NRG1)a n d
confer risk of thyroid cancer [11]. HRG-beta1c is one of
the NRG1 isoforms and interacts with tyrosine kinase to
increase its phosphorylation on tyrosine residues,
playing critical roles in the growth and development of
multiple organ system; (5) It was repeatedly observed
that the rs965513 at 9q22.33 were the strong association
signal for NMTC in European people [16-19] and it was
proposed that the rs965513 might linked to the nearest
thyroid transcription factor of forkhead family (FOXE1)
gene, which likely plays a crucial role in thyroid morpho-
genesis; furthermore, some research indicated that
rs1867277 within the FOXE1 5′ UTR is also a causal vari-
ant in thyroid cancer susceptibility [16,20]; (6) Finally,
both rs944289 and rs116909374 on 14q13.3 were ob-
served to be strongly associated with NMTC in European
people [11,16-19,21]. Nonetheless, all these genetic asso-
ciations found by the genome-wide association studies
have not been investigated in a family based study.
In addition, a few potential regions for harboring an
fPTC gene have been reported: chromosomal region
1q21 linked to fPTC with papillary renal neoplasia [22],
2q21 linked to familial NMTC type 1 syndrome [23],
and the telomere abnormalities and chromosome fragil-
ity might display in fPTC family [24]; Specifically, famil-
ial NMTC and its relationship with familial MNG are
recognized as distinct clinical entities, and the molecular
pathophysiology of MNG and PTC is different, indeed
MNG1 is located at 14q [25]; however, one study in a
kindred with MNG and PTC suggested that 14q32
linked to a form of inherited MNG syndrome with a sig-
nificant risk of progression to PTC [26].
In the present report we studied 2 PTCs and 3 MNGs
obtained from members of one Chinese family. This fam-
ily was ascertained through initial identification of the pro-
band, a 35-year-old men (III2, Figure 1). The probands’s
mother, 5 maternal aunts and 1 younger first cousin were
diagnosed with MNG or PTC by different hospitals in
China. The mode of inheritance in the family appeared to
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understanding of the PTC predisposition, based on the re-
cent progresses in genetic studies about PTC, we analyzed
in this Chinese family (1) the point mutations of the BRAF
and RET; (2) the possible susceptibility loci to sporadic
PTC; and (3) the suggested potential fMNG syndrome
with PTC risk region.
Methods
Patients
The fMNG with PTC pedigree is reported in Figure 1.
The clinical and pathological findings are summarized in
Table 1.
The study protocol was approved by the Review Board
of Clinical Research of the Sichuan Provincial hospital,
and by the Research & Ethics Committee of Sichuan
Medical Research Institution. The blood samples were
collected from the proband (III2), proband’s parents (II1
& 2) and maternal aunts (II5, 8, & 10) with their written
informed consent.
A 35-year-old man (Figure 1 III2) came to our observa-
tion: the man complained both his lymph nodes containing
palpable lump for more than 10 days, initial ultrasound ex-
aminations revealed an 1.9×1.4 cm solid mass with irregu-
lar & indefinite border, sand calcification and blood flow in
his right neck, and also 2 small nodule goiters in his left
neck; The thyroid function tests showed the man was
euthyroid; both the fine needle aspiration cytological and
thyroidectomy specimen pathologic examinations disclosed
that the architecture and nuclear features of the neoplasm
in his both necks were typical for PTC (Figure 2A) and
immunohistochemical staining confirmed the diagnosis
(Figure 2B, C, D); After the total thyroidectomy and radio-
active iodine treatment, the patient is now doing well.
Interestingly, in terms of fMNG with PTC, the patient’s
mother is diagnosed with MNG in bilateral thyroid and
underwent a total thyroidectomy in Chongqing, China
(Figure 1 II2). Both of the patient’s maternal twin aunts
and a younger male cousin were diagnosed with MNG
and PTC by different hospitals in Beijing and Chongqing,
China, respectively; the other two maternal aunts were di-
agnosed with MNG by different hospitals in Chengdu and
Dazhou, China, respectively (Figure 1 II8&10).
DNA extraction
The whole blood was collected from the medial cubital
vein into heparin anticoagulant tubes. The total DNA
was purified using the spin protocol of QIAamp DNA
Blood Mini Kit according to the manufacturer’s direc-
tions (Qiagen, Hilden, Germany). The purified DNA was
resuspended in TE buffer and stored at 4 °C. Gel electro-
phoresis and spectrophotometric determination were
used to DNA quantification and quality analysis. The
OD260/OD280 ratio of DNA samples were between 1.8-
2.0 and concentration was more than 100 ng/ml.
Figure 1 Pedigree of the Chinese fPTC. Circles and squares indicate female and male family members, respectively. The proband is indicated
by an arrow.
Table 1 Clinical and pathological study of the collected samples
Members Sex Age at diagnosis Histology sizes for PTCs and MNGs Surgical treatment
II1 male 64 normal
II2 female 62 bilateral MNG MNG (1.2 cm), suspicious lesion completion thyroidectomy
III2 male 35 bilateral MNG with PTC PTC in MNG, PTC (1.6 cm) completion thyroidectomy
II5 female 56 bilateral MNG with PTC PTC in MNG, PTC (1.5 cm) completion thyroidectomy
II8 female 45 bilateral MNG MNG (0.3 cm)
II10 female 41 MNG in right thyroid MNG (0.6 cm)
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The potential regions and susceptibility loci investigated
in the study were listed in Table 2. Sequencing was per-
formed on PCR-amplified products using primers (Table 2)
according to the published sequences or self-designed
with Primer Premier 6.1 (PREMIER Biosoft, Palo Alto
CA). The PCR amplifications were performed using ABI
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, CA). The PCR reaction system included 2U Pfu
DNA polymerase (Thermo Fisher Scientific Inc, USA),
50pmol of each sense and antisense primers, 1×reaction
buffer (20 mM Tris–HCl pH8.8, 10 mM KCl, 10 mM
(NH4)2SO4, 1% (v/v) Triton X-100), 250 μMd N T P ,
2.0 mM MgCl2 and 200 ng genomic DNA in a total vol-
ume of 50 μl. The PCR cycling parameters were followed
the recommendations for Pfu DNA polymerase according
to the manufacturer. Precautions were taken to prevent
PCR contamination, and indeed, in each experiment DNA
template negative samples were run in parallel. The PCR
products were resolved by electrophoresis in a 2% agarose
gel stained with ethidium bromide and purifed using the
QIAquick PCR purification kit (Qiagen). Purified PCR
products were sequenced directly in both orientations
using standard procedures with an ABI PRISM 3100 Gen-
etic Analyzer (ABI, CA). The sequences were confirmed
with two independent PCRs from two independent DNA
samples.
Results
The identification for the fMNG with PTC
The histological features of the proband’ papillary car-
cinoma were shown in Figure 2. The members of the
Chinese family were diagnosed with MNG and PTC by
different hospitals in China; the affected individuals
showed typical MNG or MNG with PTC, bilateral and
multicentric nodes. In this Chinese family, there were 2
first-degree blood relatives were diagnosed with bilateral
MNG and PTC, 5 second-degree blood relatives includ-
ing a pair of twin sisters were diagnosed with MNG or
PTC; Also among these family members, 2 men (III2
Figure 2 The histological features of the proband’s papillary carcinoma. A: The cytological feature: crowded oval nuclei, nuclear grooves,
clearing, elongation and overlapping (HE×400). B: Galectin-3 showed predominantly cytoplasmic staining with occasional nuclear staining
(×200). C: HBME1 showed positive diffuse membrane (×200). D: Cytokeratin 19 showed strong, predominantly cytoplasmic staining (×200).
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Clinical channel Primers Localization & product
BRAF at Chr7q34: 140,433,812-140,624,564(190,752 bp)
exon15: 176,372-176,490 (119 bp) K601E: 176,431(A→
G) rs121913364: 140,453,134 V600E: 176,429 (T→A)
rs113488022: 140,453,136
5′-TGCTTGCTCTGATAGGAAAATG-3′ 5′-
CCACAAAATGGATCCAGACA-3′
Chr7:140,453,250-140,453,078 (173 bp) intron:
176,315-176,371 exon15:176,372-176,487 (116 bp)
RET at Chr10q11.2: 43,572,517-43,625,799
exon5: 34,308-34,503 (196 bp) R313Q: 34,378(G→A)
rs77702891: 43,601,894 R330Q: 34,429(G→A)
rs80236571: 43,601,945
5′-CTTTCCTCACAACCCCCTCC-3′ 5′-
AGAGCGAGCACCTCATTTCC-3′
Chr10: 43,601,341-43,602, 077 (737 bp) intron: 33,
825–34,307&34,504-34,561 exon5: 34,308-34,503
(196 bp) STS: 33,825-34,398
exon8: 40,031-40,156 (126 bp) G533C: 40,105(G→T)
rs75873440: 43,607,621
5′-CCTGTGCAGTCAGCAAGAGA-3′ 5′-
CCTGTTCCCATGCCCTGATT-3′
Chr10: 43,607,577-43,608,444 (868 bp) exon8:
40,061-40,155 (96 bp) intron: 40,156-40,784&40,896-
40,928 exon9: 40,785-40,895 (111 bp)
exon10: 41,488-41,607(120 bp) C609R: 41,553(T→C)
rs77558292: 43,609,069 C609Y: 41,554(G→A)
rs77939446: 43,609,070 C611W: 41,561 (C→G)
rs80069458: 43,609,077 C618R/G: 41,580(T→C/G)
rs76262710: 43,609,096 C618S: 41,581(G→C)
rs79781594: 43,609,097 C620R: 41,586(T→C)
rs77316810: 43,609,102 C620F/S/Y: 41,587(G→A/C/T)
rs77503355: 43,609,103 C620W: 41,588(C→G)
rs79890926: 43,609,104 cds-indel: 41,562_41,588del27
rs121913313: 43,609,078_43,609,104del27
5′-GGAAACCTGGATCCCACAGG-3′ 5′-
GGGAGGGAAGTTTCATGGGG-3′
Chr10: 43,608,459-43,609,249 (791 bp) intron:
40,943-41,487&41,608-41,557 exon10: 41,488-41,607
(120 bp) STS: 41558-41733
exon12: 44,516-44,663 (148 bp) 5′-GTGGGCCCAATGTGTGGATA −3′ 5′-
CTCTTCAGGGTCCCATGCTG-3′
Chr10: 43,611,512-43,612,272 (761 bp) intron:
43,996-44,515&44,664-44,756 exon10: 44,516-44,663
(148 bp)
exon13: 46, 305–46,412 (108 bp) S765P: 46,313(T→C)
rs75075748: 43,613,829 E768E: 46,324(G→A/C)
rs78014899: 43,613,840 V778I: 46,352(G→A)
rs75686697: 43,613,868 L790F: 46,390(G→C)
rs75030001: 43,613,906 Y791F: 46,392(A→T)
rs77724903: 43,613,908
5′-CGGGGAATTTCTGTGGACGA-3′ 5′-
ATGGCAGTGTCACACCAGAG-3′
Chr10: 43,613,496-43,614,200 (705 bp) intron:
45,980-46,304&46,413-46,684 exon13: 46, 305–
46,412 (108 bp) misc_difference: 46,327
exon14: 47, 463–47,677 (215 bp) V804M: 47,480(G→A/
T) rs79658334: 43,614, 996
5′-GAGGCAGAGAGCAAGTGGTT-3′ 5′-
AATAGCACGAGTCGTCAGGC-3′
Chr10: 43,614,767-43,615,517 (751 bp) intron:
47,251-47, 462&47,678-48,001 exon14: 47, 463–
47,677 (215 bp)
exon15: 48,013-48,135 (123 bp) S891A: 48,076(T→G)
rs75234356: 43,615,592 cds-indel:
48,051_48,053delAGCinsTTT rs121913306
43,615,567_43,615,567delins R897Q: 48,095(G→A)
rs76087194: 43,615,611 cds-indel: 48,097_48,108del12
rs121913309: 43,615,613_43,615,624del12
5′-TCTCACAGGGGATGCAGTATCTG-
3′ 5′-GAGGCTGAGCGGAGTTCTAATTG-3′
Chr10: 43,615,159-43,615,837 (679 bp) exon14:
47,643-47,677 (35 bp) intron: 47,678-48,012&48,136-
48,321 exon15: 48,013-48,135 (123 bp)
exon16: 49, 878–49,948 (71 bp) M918T: 49,900(T→C)
rs74799832: 43,617,416 R912P: 49,882(G→C/T)
rs78347871: 43,617,398
5′-GCTCCAGCCCCTTCAAAGAT-3′5′-
CTTTGAGCAGTTTGGGGCAC-3′
Chr10: 43,617,229-43,617,941 (713 bp) intron:
49,713-49, 877&49, 949–50,425 exon16: 49,878-
49,948 (71 bp) STS: 49,832-50,007
exon17: 51, 603–51,740 (138 bp)R972G: 51,715(A→G)
rs76534745: 43,619,231
5′-CTCTGATGGGAGTGGCTTGG-3′5′-
CCACTCAGGCACCCCTTAAC-3′
Chr10: 43,618,871-43,619,601 (713 bp) intron:
51,355-51, 602&51,741-52,085 exon17: 51, 603–
51,740 (138 bp)
2q35
DIRC3 (noncoding RNA):218,148,746-218,621,316
(472571 bp)rs966423:218,310,340
5′-CGGCCTCGACCAACACTTAT-3′
5′-ACTGGGCGTCTCAACTACAATCTG −3′
Chr2: 218,310,115-218,310,537(423 bp) located in
the intron region of DIRC3,
5q24
Pre-miR-146a: 159,912,359-159,912,457(99 bp)
rs2910164: 159,912,418
5′-ATTTTACAGGGCTGGGACAG-3′ 5′-
TCTTCCAAGCTCTTCAGCAG-3′
Chr5: 159,912,297-159,912,523(227 bp)
8q24
rs4733616: 128,662,095 5′-CACCGGGGATTGGAAGAGATAAG-3′
5′- TGAAGCCACAGGGGAGAAAAGT −3′
Chr8:128,661,750-128,662,159(410 bp)
8p12
NRG1 transcript variant HRG-beta1c: 31,496,820-
32,622,558(1,125,738 bp) rs2439302: 32,432,369
5′-AATGCAAGAATGGCCTAACACAAT-3′
5′-AACCTGGGGSSSSSTCTGAAGC-3′
Chr8: 32,432,326-32,432,660(334 bp) located in
intron of NRG1
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nosed with MNG and PTC (Figure 1); As the family
members resided in different cities and denied radiation
exposure, no other neoplasia syndromes or somatic gen-
etic alterations in the tumor DNA was observed,
according to diagnostic criteria of familial MNG with
PTC [6], we considered the Chinese family presented
hereditary predisposition to PTC.
The comparison of the susceptibility loci
In the current study, we investigated the exon 15 of
BRAF, since several SNPs in the genomic region were
reported to contribute to PTC in a Chinese population
[8] and the transversions in exon 15 are the common
morphotype-specific mutation in adult sporadic PTC.
The results were shown in Table 3: the examined BRAF
sequences involved these susceptibility loci carried no
risk alleles and were the same as common TT at
BRAF
T1799A and AA at BRAF
A1801G. No any other gen-
etic mutation was found in the family members.
We also investigated all the known RET susceptibility
loci to family thyroid diseases in this Chinese family. Ei-
ther, no known RET susceptibility loci was mutational in
the family members. However, it needs to mention that in
the genomic regions which we sequenced, the RET introns
contained certain differences among the family members,
such as introns between exon 4 and 5 (rs35800403 &
rs2742243), between 11 and 12 (rs2256550), between 14
and 15 (rs11238441 & rs2472737) (Table 3), and also, there
was a new C to T heterozygous allele in the upstream of
rs111306965 in the genome of memberII8 andII10 by re-
peatedly sequencing. Additionally, rs1800863 in exon 15
contained variants of synonymous code substitution in the
genome of several family members (II2, II5 & II10).
With respect to the other susceptibility loci identified, as
shown in Table 3, all the members from the Chinese fam-
ily had equal sequences in the (1) DIRC3 susceptibility
locus at 2q35, (2) Pre-miR-146a susceptibility locus at
5q24, (3) NRG1 transcript variant HRG-beta1c susceptibil-
ity locus at 8p12, (4) susceptibility loci of 8q24, and (5)
susceptibility loci of 9q22. Noticeably, all the family mem-
bers including the proband’s father without thyroid disease
were homozygous for the risk alleles of (1) rs966423 (CC)
in DIRC3, (2) rs2910164 (CC) in Pre-miR-146a and (3)
rs2439302 (GG) in HRG-beta1c; While all these members
from the Chinese family contained no risk allele of (4)
rs4733616 at 8q24, (5) rs965513 and rs1867277 at 9q22.
For the susceptibility loci of 14q13.3, as 14q was
reported to be specifically linked with MNG1 and a form
of MNG with PTC [25,26], it is worth to mention that
the risk T allele of rs944289 was presented in the se-
quences of the most family members affected with thy-
roid disease (II2 & II8, MNG; II5 & III2, MNG with
PTC; Table 1). The sequence result in Table 3 showed
that both MNG with PTC family members II5 and III2
were heterozygous (CT) and the 2 MNG family mem-
bers II2 and II10 were homozygous (TT) at rs944289
locus (Table 3). While for another susceptibility locus of
rs116909674 at 14q13.3 which we checked, none of the
studied Chinese family members carried the risk alleles.
Discussion
The Chinese family presented hereditary predisposition
to PTC, but currently the genetic incline to fPTC is un-
known. With the aim of understanding the involvement
of genetic factors underlying fPTC, we analyzed the
reported possible PTC susceptibility genetic regions by
sequence in the Chinese family members who consented
to join the study. First, it is worthy to mention that no
risk allele of rs965513 (A) or rs1867277 (A) at 9q22 was
observed among the Chinese family members. These
susceptibility loci of FOXE1 at 9q22 were related to
radiation-induced PTC [19], hence it may be reasonable
that the FOXE1 risk alleles were not presented in the fa-
milial form of MNG with PTC, as the members denied
radiation exposure and resided in quite different envir-
onment. Either, the Chinese family members carried no
risk allele of rs4733616 (T) at 8q24 which has been shown
to be associated with sporadic PTC in Europeans [14-16],
but the pathogenic role of the allele is currently unknown.
Table 2 Sequences of the primers (Continued)
9q22.33
rs965513:100,556,109 5′-CCGGCTTGAGTTCAGGTATGTAGT-3′
5′-CCAGGCTCAGGTTATGTCTTTGTT-3′
Chr9: 100,555,758-100,556,177(420 bp)
9q22
FoxE1: 100,615,537-100,618,997(3,460 bp)rs1867277:
100,615,914
5′-AGACCAGCTGCAGCCACCCCAACC-3′
5′-GTCTCGCCGCGCTCTTCCTTCACG-3′
Chr9: 100,615,806-100,616,270(465 bp)located in
the STS of FoxE1
14q13.3
rs944289: 36,649,246 5′-CCAGTGGCCCCGCAGGTT-3′5′-
GAAAAGCACGTCTCCCCACAGTCC-3′
Chr14: 36,648,944-36,649,435(492 bp)
rs116909374: 36,738,361 5′-TGTAATGGCAGCTCTTGACCTT-3′ 5′-
ACCTTTGATTGCCCTTAGTTTGA-3′
Chr14: 36,738,229-36,738,674(446 bp)
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Chromosome BRAF at Chr7q34 RET at Chr10q11.2: 43,572,517-43,625,799
rs121913364 rs113488022 rs35800403 rs2742243 rs77702891 rs80236571 rs75873440 rs77558292 rs77939446 rs80069458
Locus 140,453,134
exon15
140,453,136
exon15
43,601,415
intron
43,601,749 intron 43,601,894
exon5
43,601,945
exon5
43,607,621
exon8&9
43,609,069
exon10
43,609,070
exon10
43,609,077 exon10
Allele A:germline G:
germline somatic
A→G missense
A:germline;
somatic C:somatic
T:germline T→A
missense
G/C T/C A:germline
G:germline
G →A
missense
A:germline
G:germline
G→A
missense
G:germline
T:germline
G→T
missense
T:germline
C:germline
T→C
missense
G:germline A:
germline G →A
missense
C:germline
G:germline
C→G
missense
II1 normal TT AA GC TC GG GG GG TT GG CC
II2 MNG TT AA GG TT GG GG GG TT GG CC
III2 PTC TT AA GC TC GG GG GG TT GG CC
II5 PTC TT AA GG TT GG GG GG TT GG CC
II8 MNG TT AA GC TC GG GG GG TT GG CC
II10 MNG TT AA GG TT GG GG GG TT GG CC
Chromosome RET at Chr10q11.2: 43,572,517-43,625,799
rs76262710 rs79781594 rs77316810 rs77503355 rs79890926 rs121913313 rs2256550 rs75075748 rs78014899 rs75686697 rs75030001
Locus 43,609,096
exon10
43,609,097
exon10
43,609,102
exon10
43,609,103 exon10 43,609,104
exon10
43,609,104
exon10
43,611,865
exon12
43,613,829
exon13
43,613,840
exon13
43,613,868
exon13
43,613,906
exon13
Allele C:germline G:
germline T:
germline T→
C&T→G
missense
C:germline G:
germline G→C
missense
C:germline
T:germline
T→C
missense
A:germline C:germline
G:germline T:germline
G→A& G→C& G→T
missense
C:germline
G:germline
C→G
missense
not
availiable
cds-indel
T/C intron C:germline
T:germline
T→C
missense
A:unkown C:
somatic G:
germline G →A&
G →C cds-synon
A:germline
G:germline
G→A
missense
C:unkown
G:germline
G→C
missense
II1 normal TT GG TT GG CC no del TC TT GG GG GG
II2 MNG TT GG TT GG CC no del TT TT GG GG GG
III2 PTC TT GG TT GG CC no del TC TT GG GG GG
II5 PTC TT GG TT GG CC no del TT TT GG GG GG
II8 MNG TT GG TT GG CC no del TC TT GG GG GG
II10 MNG TT GG TT GG CC no del TT TT GG GG GG
Chromosome RET at Chr10q11.2: 43,572,517-43,625,799
rs77724903 rs79658334 rs11238441 new rs2472737 rs121913306 rs75234356 rs76087194 rs121913309 rs1800863 rs78347871
Locus 43,613,908
exon13
43,614,996
exon14
43,615,382
intron
43,615,404 intron 43,615,505
intron
43,615,567
exon15
43,615,592
exon15
43,615,611
exon15
43,615,613
exon15
43,615,633
exon15
43,617,398
exon16
Allele A:germline T:
germline A→T
missense
A:unkown G:
germline T:
germline G→A
&G→T missense
C/T C/T G/A AGC:
germline
TTT:somatic
cds-indel
G:germline
T:germline
T→G
missense
A:germline
G:germline
G→A
missense
not availiable cds-
indel
not
availiable C/
G cds-synon
C:germline
G:germline
G→C
missense
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8Table 3 Sequences of susceptibility loci in the family members (Continued)
II1 normal AA GG CC CC GA AGC TT GG no del CC GG
II2 MNG AA GG CT CC GG AGC TT GG no del CG GG
III2 PTC AA GG CC CC GA AGC TT GG no del CC GG
II5 PTC AA GG CT CC GG AGC TT GG no del CG GG
II8 MNG AA GG CC CT GA AGC TT GG no del CC GG
II10 MNG AA GG CT CT GG AGC TT GG no del CG GG
The SNP alleles are shown as the reference/variant, referring to NCBI Build 36.3; the common to mutant is showed by “→”; the risk allele is indicated with an asterisk and outlined if presented in the family members,
and the different sequences among the family members are shadowed.
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8Our results verified that, for the predisposition to familial
form of PTC and radiation-related PTC, their mechanism
of PTC susceptibility did not completely overlap each
other, since the genetic determinants associated with
radiation-related PTC were not presented in the Chinese
family members with PTC and MNG.
It is also noticeable that all the family members were
homozygous for the risk alleles of rs966423 (CC) at 2q35,
rs2910164 (CC) at 5q24 and rs2439302 (GG) at 8p12. All
these susceptibility loci have been reported to associate
with sporadic PTC [11,13], but currently the pathogenic
functions of these alleles are not known well. We think all
these risk alleles might contribute jointly to the develop-
ment of MNG and PTC in the Chinese family members;
while considering the risk alleles also presented in the pro-
band’s father with normal thyroid, it is possible that differ-
ent pathogenic mechanisms exist to activate the tumor
transformation in the family members with thyroid disease.
Interestingly, we observed that the frequency of T risk
allele of rs944289 at 14q13.3 locus was increased in these
MNG and PTC Chinese family members (C: T=0.4:0.6 vs
0.571:0.429 in normal people). Several studies suggested
the possible genetic predisposition of 14q to familial PTC
[25] while no association between the radiation-related
PTC and 14q13.3 [19]. Also, family nontoxic MNG locus
maps to chromosome 14q [24]. Further research suggested
that rs944289 was located in a CEBP-alpha/CEBP-beta
binding element in the 5-prime UTR of a thyroid-specific
lincRNA gene, papillary thyroid carcinoma susceptibility
candidate 3 (PTCSC3), PTCSC3 had the characteristics of
a tumor suppressor, the rs944289 T risk allele reduced
PTCSC3 promoter activation and thereby predisposes to
PTC [21]. Nevertheless, the tumor suppression mechan-
ism of PTCSC3 is currently unknown. In addition, the thy-
roid transcription factor of NK2 homeobox 1, NKX2-1,i s
also located in the 14q13.3; NKX2-1 regulates the expres-
sion of thyroid-specific genes involved in morphogenesis.
But how rs944289 was associated with NKX2-1 remains to
be investigated. Also, we investigated PTC susceptibility
locus of rs116909374 (T) locating between PTCSC3 and
NKX2-1 at the same 14q, the family members carried no
risk allele at all. Hence, our current work implied the pos-
sible role of rs944289 in familial MNG with PTC.
Whereas, it is surprise that heterozygosity as CT rather
than homozygosity as TT presented in the fPTC family
members; the same phenomenon was once suggested as a
possible special form of genetic epistasis in the rs2910164
allele of pre-miR-146a gene [12], which may also contrib-
uted to this Chinese fMNG with PTC as shown by the
study. Briefly, our results in the Chinese family agreed that
rs944289 but not rs116909374 at 14q13.3 locus might be
associated with genetic predisposition to familial form of
MNG with PTC; it will be intriguing to further analyze the
pathogenic link between rs944289 and the disease.
As we failed to detect somatic genetic alterations in
the tumor DNA, such as the BRAF and RET proto-
oncogene in the Chinese family members, in the current
study, we investigated the genomic region containing the
BRAF susceptible variants in sporadic PTC, and also all
the known RET susceptibility loci to thyroid diseases
(Tables 2 and 3). Our sequencing results confirmed that
the BRAF and RET mutations were not germline muta-
tions or susceptibility genetic events in this Chinese fam-
ily. However, we noticed that in the sequenced RET
genetic region, several different heterozygous alleles
were presented among the Chinese family members, and
most alleles were in the intron region. Recently, the
chromosomal fragile sites breakage was proposed to
cause PTC by forming chromosome rearrangement [26].
The chromosomal fragile sites are regions of the genome
with a high susceptibility to forming DNA breaks and
are often associated with cancer. Exposure to a variety of
external factors such as chemotherapeutic, dietary and
environmental compounds can induce and accelerate
the fragile site breakage. Several intron regions of RET
were identified as DNA breakage region. Hence, we are
wondering if it is possible that the polymorphisms of in-
trons could link to the structural difference in the RET
region and could impact the related chromosome archi-
tecture and thyroid gene expression, albeit there was no
RET mutation in the cancerous thyroid. Interestingly,
there were 2 related facts to be considered: (1) it was
shown that transfecting thyroid cells with RET produced
morphological changes in nuclei that mimicked those
seen in PTC [27]; (2) it is curious that the RET gene is
not expressed in the thyroid follicular cells from which
PTC develops, but rearrangements of the RET are found
in PTC cases [28]. Hence, we think it will be intriguing
to investigate the association between the genomic
structural of RET region and the regulation mechanism
of RET.
Our work may provide additional evidence to the gen-
etic predisposition to familial form of MNG with PTC.
Due to unavailability of samples and the complex of
pathogenesis, the current studied Chinese family was
small and limited. Nonetheless, for complex diseases like
PTC, there may be many genes influencing risk as well
as the effects of environment, also, it is much more diffi-
cult to collect pedigrees with multiple affected relatives
and there is no guarantee of the same (or any) gene
(SNP) segregating in these family. To provide insights
into the genetic risk factors for familiar PTC, more re-
searches are needed.
Conclusions
Based on our current investigation in the Chinese fMNG
with PTC, the risk allele homozygote of rs966423 (CC)
at 2q35, rs2910164 (CC) at 5q24 and rs2439302 (GG) at
Liao et al. BMC Endocrine Disorders 2013, 13:48 Page 9 of 11
http://www.biomedcentral.com/1472-6823/13/488p12 could contribute to the fMNG with PTC, while the
other identified risk alleles for sporadic PTC or
radiation-related PTC might not be involved. Also, cor-
responding to the previous studies on the association be-
tween chromosome 14q and fMNG with PTC, our work
approved that rs944289 but not rs116909374 at 14q13
locus might be associated with genetic predisposition to
a Chinese family MNG with PTC. Though several differ-
ent heterozygous alleles in the RET introns presented,
the common BRAF and RET mutations were not suscep-
tibility genetic events in this Chinese family.
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